Business Context and Reporting Period
Camp4 Therapeutics Corp (CAMP) filed a Form 8-K on March 12, 2025, reporting corporate governance changes. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cambridge, MA.
Key Financial Metrics
This filing is a Current Report regarding the appointment of directors and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Board Expansion: The Board of Directors increased its size from ten to twelve members.
- New Appointments:
- Douglas Williams, PhD: Appointed as a Class I director, effective March 17, 2025. He has been appointed to the Audit Committee.
- Murray Stewart, DM FRCP: Appointed as a Class II director, effective March 17, 2025.
- Compensation Grants: Each new director was granted an option to purchase 17,787 shares of common stock under the 2024 Equity Incentive Plan. These options vest in monthly installments over three years, subject to continued service. Both directors will receive standard cash retainers, with Dr. Williams receiving an additional retainer for Audit Committee service.
Outlook, Risks, and Management Commentary
Management stated that Dr. Williams' extensive experience in executive roles within the biotechnology industry and leading therapeutic development qualifies him for the Board. Similarly, Dr. Stewart's background in biopharmaceutical leadership, including research, clinical development, and regulatory strategy, was cited as a key qualification. The filing notes that neither director is subject to arrangements with other persons regarding their appointment and that no transactions exceeding $120,000 have occurred with either director since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the effective date of the new director appointments (March 17, 2025) and their specific class designations.
- Review the vesting schedule for the 17,787 stock options granted to each new director.
- Confirm the total number of Board members is now twelve.
- Check for any potential conflicts of interest given Dr. Williams' prior role at Codiak BioSciences, which filed for Chapter 11 bankruptcy in March 2023.
- Consult the Company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.